Ana N. Forsythe

Ana N. Forsythe

Auto-generated profile, based on publicly available information

Ana N. Forsythe

RTI International, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in Journal of Community Genetics
Verified
Journal Article
Closed access
PDF file
RWRebecca Wright
Rebecca Wright
ECEmily Cheves
Emily Cheves
SWSa’NEaldra T. Wiggins
Sa’NEaldra T. Wiggins
RMRebecca R. Moultrie
Rebecca R. Moultrie
AFAna Forsythe
Ana Forsythe
HPHolly Landrum Peay
Holly Landrum Peay

24 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SPSarah Nelson Potter
Sarah Nelson Potter
CPCarlos Petzold
Carlos Petzold
KGKatie Garbarini
Katie Garbarini
AFAna N. Forsythe
Ana N. Forsythe
EJElizabeth Jalazo
Elizabeth Jalazo
AWAnne Wheeler
Anne Wheeler
Background: Epilepsy is a core feature of Angelman syndrome (AS) and a major contributor to morbidity and caregiver burden. The current study provides updated caregiver-reported data on seizure characteristics, triggers, and management in AS.Methods: Caregivers of 130 individuals with AS enrolled in the Linking Angelman and Dup15q Data for Expanded Research (LADDER) Database completed an online questionnaire assessing seizure characteristics, age at first seizure and diagnosis, perceived triggers, and management strategies. Participants were grouped by molecular subtype (deletion vs. non-deletion). Descriptive statistics and group comparisons were conducted.Results: Seizures were more frequently reported in individuals with deletion subtypes compared to those with non-deletion subtypes. The most common seizure-related manifestations (myoclonic, atonic, and atypical absence features) did not differ between groups. Individuals with deletion subtypes experienced earlier epilepsy diagnosis than those with non-deletion subtypes, though age at first seizure prompting medical attention did not differ significantly between the groups. About half of caregivers were unsure of seizure triggers; among identified triggers, illness or infection with a fever was most common. Pharmacological treatment was the primary management approach, with levetiracetam most frequently reported. Side effects were the most common reason for medication discontinuation, and only 69% of caregivers reported access to or use of an acute seizure rescue medication.Conclusions: Caregiver-reported data from the LADDER Database provide an updated characterization of seizures in AS. Gaps in trigger identification and availability or use of rescue medications highlight opportunities to improve standard-of-care implementation in AS.

Verified
Journal Article
Open access
PDF file
ECEmily Cheves
Emily Cheves
HFHannah E. Frawley
Hannah E. Frawley
AGAngela Gwaltney
Angela Gwaltney
AFAna N. Forsythe
Ana N. Forsythe
SSSamantha Scott
Samantha Scott
HPHolly Landrum Peay
Holly Landrum Peay
Research programs can interface with public health programs to generate innovation, yet it is critical to ensure processes that support research activities without infringing on protected data. Genomic newborn screening (gNBS) research programs require reliable methods to link parental consents to the correct newborn screening (NBS) specimen. Early Check is a gNBS research program in North Carolina that uses the residual dried bloodspot (DBS) samples stored at the North Carolina State Laboratory of Public Health (NCSLPH) to screen babies for serious health conditions. Early Check created a systematic approach to match research consents with NBS DBS samples utilizing a fuzzy matching algorithm and manual review of prospective matches utilizing a decision tree. Between 28 September 2023, and 10 June 2025, Early Check received parental consents for 4279 newborns. Of those, 614 (14%) had discrepancies that required further review. More than half of these (349, 57%) required outreach to the consenting parent to resolve differences in information such as name, infant sex, or contact details. The use of probabilistic matching, a decision tree, and structured staff review provides a feasible approach for accurately identifying samples from consented NBS participants.

15 June 2026 in Pediatric Neurology
Verified
Journal Article
Closed access
SPSarah Potter
Sarah Potter
CPCarlos Petzold
Carlos Petzold
KGKatie Garbarini
Katie Garbarini
AFAna N. Forsythe
Ana N. Forsythe
EJElizabeth Jalazo
Elizabeth Jalazo
AWAnne Wheeler
Anne Wheeler

2 November 2026 in Genetics in Medicine Open
Verified
Journal Article
Open access
HCHeidi Cope
Heidi Cope
RMRebecca R. Moultrie
Rebecca R. Moultrie
AFAna N. Forsythe
Ana N. Forsythe
HPHolly Landrum Peay
Holly Landrum Peay
DLDownie Lilian
Downie Lilian
SHSula Hood
Sula Hood